Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

Custodio, Ana; Casado, Antonio; Vidart, José Antonio; Coronado, Pluvio; Martín, Miguel; López-Tarruella, Sara; Puente, Javier; Fernández, Cristina; Dı́az-Rubio, Eduardo

doi:10.1007/s12094-011-0629-6

Cited by 8 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Wong et al, 2008). Besides, some others significantly dysregulated in solid tumor and have been identified as tumor suppressor activities (Lee and Dutta, 2009;Garcia-Saenz et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia

Maimaiti

Abudoukeremu

Tie

et al. 2015

Gene

View full text Add to dashboard Cite

“…(Wong et al, 2008). Besides, some others significantly dysregulated in solid tumor and have been identified as tumor suppressor activities (Lee and Dutta, 2009;Garcia-Saenz et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia

Maimaiti

Abudoukeremu

Tie

et al. 2015

Gene

View full text Add to dashboard Cite

“…However, recently, according to a variety of biomarkers it was suggested to represent only 2-3% of total carcinomas (16). Nevertheless the different images that appeared following staining with antibodies to Ep would suggest novel subtypes of ovarian carcinomas.…”

Section: Discussionmentioning

confidence: 99%

“…Ovarian cancer is the most lethal gynecological cancer in women because early detection is extremely difficult (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14) and because it is resistant to most chemotherapic drugs (15)(16)(17). The average lifespan after detection is 40.8 months for serous cancer, 21.3 months for clear cell carcinomas, 17.6 months for mucinous carcinomas and 50.9 months for endometrioid ovarian carcinomas (11).…”

Section: Introductionmentioning

confidence: 99%

Epiregulin as a marker for the initial steps of ovarian cancer development

Amsterdam

Shezen²,

Raanan³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. Epiregulin (Ep) was found to be produced in noncancer ovarian cells in response to gonadotropin stimulation as well in ovarian cancer cells in an autonomous manner. However, there were no systematic follow-up studies of Ep expression in the development of different stages of ovarian cancer. Using specific antibodies to Ep and the indirect immunocytochemistry methods, we found that in normal ovary the staining for Ep was mainly confined to the epithelial cells, while the stromal cells were only occasionally and moderately stained. In contrast in benign serous and mucinous tumors most of the tumor cells showed a clear staining in the cytoplasm. In borderline serous and mucinous tumors the staining was much more intensive, and appear occasionally in aggregated form. In serous, mucinous and endometrioid carcinomas labeling remain high, with more frequent aggregated form. It is suggested that follow-up of the expression of Ep can serve as a reliable early indication of the development of ovarian cancer. Moreover, the cytoplasmic aggregation of Ep may suggest a specific mechanism of the release of this growth factor to the extracellular space in order to exert its autocrine and paracrine effect on the family of the EGF receptors.

show abstract

“…The worse prognosis of mucinous ovarian cancer arises probably from the fact that this type of cancer is largely platinum and taxane resistance (reviewed in refs. 16,25). Clear cell carcinoma is the second most common type of ovarian epithelial cancer representing 5% of ovarian carcinomas (26).…”

Section: Introductionmentioning

confidence: 99%

Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer

Amsterdam

Shezen²,

Raanan³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. We examined the possibility that the localization of phosphorylated ERK1 and ERK2 (pERK1/2) can serve as a marker for the development of benign and borderline tumors as well as carcinoma of the ovary by an immunohistochemical method on ovarian paraffin sections, obtained from women aged 41-83 years. In normal tissue, 28.3% of nuclei were labeled, mainly confined to the epithelial cells at the surface of the ovary. In benign serous tumors, the label rose to 55.0%, while the intensity of the staining was weak. In contrast, in borderline serous tumors and in ovarian serous carcinoma (stage II) 52.1% and 70.3% of nuclei, respectively, were labeled with a high intensity. In mucinous benign tumors, the number of labeled nuclei was as in the control, but in addition, 49.4% of the cells demonstrated high concentration of pERK1/2 in aggregated form that was evident in the cytoplasm of the cells. In the mucinous and endometrioid ovarian carcinomas (stage II) very intensive labeling was found in 60% and 77.3% of cells, respectively. It is, therefore, suggested that since nuclear pERK1/2 can be mitogenic, it can serve as a reliable marker for the progression of ovarian cancer. Interestingly, the intense labeling of pERK1/2 was mainly confined to the peripheral areas of ovarian endometrioid carcinoma (stage II). In addition, all tumor cells in this class of cancer were positively stained with mutated p53. It seems, therefore, that immunohistochemical staining of normal and ovarian tumor cells with anti-pERK1/2 is a reliable marker for early detection of the cancer, which may assist in the early diagnosis and prognosis of this lethal disease.

show abstract

Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

Cited by 8 publications

References 52 publications

MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia

MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia

Epiregulin as a marker for the initial steps of ovarian cancer development

Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer

Contact Info

Product

Resources

About